Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) Revenue (2017 - 2026)

Lexaria Bioscience's Revenue history spans 10 years, with the latest figure at $20000.0 for Q1 2026.

  • Quarterly results put Revenue at $20000.0 for Q1 2026, down 88.51% from a year ago — trailing twelve months through Feb 2026 was $368000.0 (down 30.03% YoY), and the annual figure for FY2025 was $705923.0, up 52.05%.
  • Revenue for Q1 2026 was $20000.0 at Lexaria Bioscience, down from $174000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $183923.0 in Q4 2024 to a low of $1841.0 in Q3 2022.
  • The 5-year median for Revenue is $90867.5 (2022), against an average of $96788.6.
  • The sharpest move saw Revenue crashed 99.97% in 2022, then surged 1569.8% in 2023.
  • Year by year, Revenue stood at $97735.0 in 2022, then skyrocketed by 54.78% to $151278.0 in 2023, then increased by 21.58% to $183923.0 in 2024, then decreased by 5.4% to $174000.0 in 2025, then plummeted by 88.51% to $20000.0 in 2026.
  • According to Business Quant data, Revenue over the past three periods came in at $20000.0, $174000.0, and $174000.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.